EEStor, Inc. (EEStor) had a conference call this afternoon with ZENN Motors and Evans Capacitor. The objective was to try and assess what had been accomplished at Evans Capacitor since he received the EEStor layer test samples. Evans Capacitor test results, while only verbally expressed with no specifics as to the test equipment used, testing protocols seem to have been of limited value. EEStor started over seven years ago to develop testing systems and procedures and it has taken substantial ... read more
Rambus Inc. (NASDAQ:RMBS) and Micron Technology, Inc. (NASDAQ:MU) today
announced they have signed a broad patent cross license agreement. Under
the agreement, Micron gains the right to use any Rambus patent for the
manufacture of specified integrated circuit products, including any
memory integrated circuit products. Certain ... read more
TUSTIN, CA -- (Marketwired) -- 12/09/13 -- Nexalin Technology makes the mainstream news on WPEC-TV CBS 12 News. CBS 12 featured a breaking news piece on Nexalin Technology and how it has been helping a long time depression patient of Dr. Mark Agresti, psychiatrist and owner of Mark Agresti's M.D. & Associates. Dr. Agresti is one of many medical professionals that have set up a Nexalin treatment center within his practice, and he is continuously getting positive results from ... read more
At Fire Protection Group, Inc., you'll find a team with incredible skill at servicing and installing fire alarm systems throughout Southern California. Their team has over 200 years of combined experience providing emergency necessities like fire sprinkler systems for projects that range from sprawling university campuses to office and residential buildings. Perhaps best of all, their services extend from product design to fire watch, consulting, and fire sprinkler inspection, ensuring that the people and property under your care will always ... read more
ClipperCreek today introduced its latest product, the HCS-40, a 30 Amp,
240 Volt Level 2 electric vehicle charging station. The HCS is
indoor/outdoor rated and designed to be the most rugged station
available. With standard 25 feet of charging cable, a no strings
attached 3 year ... read more
Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that a joint panel of members from the Gastrointestinal Drugs and Drug Safety and Risk Management Advisory Committees of the United States (U.S.) Food and Drug Administration (FDA) voted to recommend approval of Takeda's vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). All 21 committee members voted that based on currently available efficacy and safety ... read more
Ed4Online will offer the Thuze library of eTextbooks to students across the country under the terms of a new partnership with Bridgepoint Education, Inc. (NYSE: BPI). Ed4Online is a provider of continuing education courses to traditional colleges and universities such as Rutgers, Auburn, Towson and Texas Southern University. The partnership between Bridgepoint Education and Ed4Online will result in decreased distribution costs and provide students with convenient digital access to textbooks that were previously unavailable to them online.
"We are ... read more
Pomerantz Grossman Hufford Dahlstrom & Gross LLP is investigating claims on behalf of investors of OSI Systems, Inc. ("OSI Systems" or the "Company")(NASDAQ: OSIS). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 237.
The investigation concerns whether OSI Systems and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On Friday, December 6, 2013, the company disclosed that the Transportation Security Administration canceled ... read more
Pharmaceuticals, Inc., the leader in the development of selective
histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes,
today announced that positive interim clinical data from the two
proof-of-concept clinical trials with selective HDAC6 inhibitor,
ricolinostat (ACY-1215), were presented at ... read more
ACell, Inc., a leading regenerative medicine company focused on the development, manufacturing and commercialization of tissue repair products, today announced that it has nearly doubled the size of its Board of Directors with the appointment of three members. The additions of Jon T. Tremmel, Steven P. Mullins and James D'Orta, M.D. increase the number of directors from four to seven.
Jon T. Tremmel held several senior leadership positions with Medtronic, Inc. until his retirement in April 2007, including serving as ... read more
Guidewire Software, Inc. (NYSE:GWRE) a provider of software products to
Property/Casualty insurers, today announced that Andrew W. F. Brown
(“Andy”) has been elected as a Director to Guidewire Software's Board.
"We are pleased to welcome Andy Brown to our Board
... read more
Janssen Research & Development, LLC (Janssen) today announced data from a study published in The Lancet Oncology, evaluating the safety and activity of ibrutinib as a single-agent therapy in patients over the age of 65 with previously untreated chronic lymphocytic leukemia (CLL, N=29) or small lymphocytic lymphoma (SLL, N=2). The study met its primary endpoint of safety, with data demonstrating treatment with ibrutinib as an initial therapy was associated with adverse events (AEs) that were predominantly Grade 1 or 2 ... read more
Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that The Lancet Oncology published results of a study evaluating ibrutinib in previously untreated elderly patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The Phase 1b/2 open-label, multicenter study evaluated 31 patients, 65 years of age and older with CLL or SLL. The primary endpoint of the study was safety, as assessed by the frequency and severity of adverse events (AEs), while the secondary objectives assessed the clinical activity of single ... read more
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, announced today that it has presented new pre-clinical data
with ALN-AT3, a subcutaneously administered RNAi therapeutic targeting
antithrombin (AT) for the treatment of hemophilia and rare bleeding
disorders (RBD), at ... read more
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of
cancer metabolism and inborn errors of metabolism, today announced that
data from its lead programs were highlighted at the American Society of
Hematology (ASH) Annual Meeting this week in New Orleans.
... read more
Data presented today by CSL Behring at the 55th Annual Meeting of the American Society of Hematology (ASH) showed Kcentra(®) (Prothrombin Complex Concentrate [Human]) was superior to plasma, the current standard of care in the U.S., in adult patients taking vitamin K antagonist therapy (VKA; e.g., warfarin) who required warfarin reversal prior to an urgent surgery or invasive procedure. Kcentra, the first non-activated 4-factor prothrombin complex concentrate (4F-PCC), was approved by the FDA in April 2013 for the urgent reversal ... read more
Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced four oral presentations given at the 55(th) Annual ASH Conference in New Orleans, with data highlighting the Company's lead drug candidate, quizartinib.
Results of the Phase 2b Randomized, Open-Label, Study of Lower Doses of Quizartinib in Subjects with FLT3-ITD Positive Relapsed Acute Myeloid Leukemia (AML): The purpose of this study is to assess the efficacy and ... read more
Levi & Korsinsky, LLP is investigating Intercept Pharmaceuticals, Inc. (NasdaqGM: ICPT) in connection with possible claims of breaches of fiduciary duty by certain members of the board of directors.
(Logo: http://photos.prnewswire.com/prnh/20120409/MM84375LOGO )
To get more information, click here: http://zlk.9nl.com/intercept-pharmaceuticals-icpt/. There is no cost or obligation to you.
If you own common stock in Intercept Pharmaceuticals, Inc. and wish to obtain additional information, please contact Eduard Korsinsky, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit ... read more
Amdocs Limited (NYSE: DOX) has filed its Annual Report on Form 20-F for the fiscal year ended September 30, 2013 (including its financial statements for such year) with the U.S. Securities and Exchange Commission. The annual report is available through the Company's website (http://www.amdocs.com/About/Pages/AnnualReport.aspx). Upon the request of a shareholder of the Company, the Company will promptly provide to such shareholder a copy of the 2013 annual report, free of charge.
(Logo: http://photos.prnewswire.com/prnh/20120722/NY44154LOGO )
For 30 years, Amdocs has ensured ... read more
NASA engineers are developing climbing legs for the International Space Station's robotic crewmember Robonaut 2 (R2), marking another milestone in space humanoid robotics.
The legless R2, currently attached to a support post, is undergoing experimental trials with astronauts aboard the orbiting laboratory. Since its arrival at the station in February 2011, R2 has performed a series of tasks to demonstrate its functionality in microgravity.
These new legs, funded by NASA's Human Exploration and Operations and Space Technology mission directorates, will ... read more